Suscribirse

Successful treatment of hepatic and mesh Aspergillosis in a neonate with giant omphalocele - 18/05/22

Doi : 10.1016/j.mycmed.2022.101245 
S.Yildirim Arslan a, Z.Sahbudak Bal a, , G.Guner Ozenen a, N.M. Bilen a, J. Naghiyev b, G. Sakul b, F. Ozkinay a, O. Ergun b, A. Ozarslan c, Z. Kurugol a
a Medical School of Ege University, Division of Infectious Disease, Department of Pediatrics, Izmir, Turkey 
b Medical School of Ege University, Department of Pediatric Surgery, Izmir, Turkey 
c Medical School of Ege University, Department of Microbiology, Izmir, Turkey 

Corresponding author at: Medical School of Ege University, Division of Infectious Disease, Department of Pediatrics, Bornova/Izmir, 35100, Turkey.Medical School of Ege UniversityDivision of Infectious DiseaseDepartment of PediatricsBornova/Izmir35100Turkey

Abstract

Aspergillosis is a rare and life-threatening fungal infection in immunocompetent children, particularly in infants. We present a case of invasive Aspergillosis (IA) that developed hepatic and mesh infection due to Aspergillus flavus following the rupture of a giant omphalocele. A male baby was born at 37 weeks of gestation with a giant omphalocele. No other congenital abnormalities were found. In the pediatric surgery operation room, the amniotic membrane seemed to be ruptured in some parts, which had been repaired within a few hours of birth. No further intervention to reduce the volume of visceral organs could be performed due to the tiny abdominal cavity. Postoperatively piperacillin-tazobactam and fluconazole were empirically initiated. Abdominal defects had been covered with polypropylene polylactic acid synthetic Mesh on postnatal day 11 to protect the organs and prevent abdominal infections. Fungal hepatic lesions were observed during surgery, and black necrotic lesions were also observed on the mesh on day 12. On the 16th postnatal day, Aspergillus flavus grew in the wound, graft, hepatic biopsy cultures. Serum galactomannan (GM) assay test was positive (GM:2.9), and voriconazole was initiated. All necrotic lesions resolved with liposomal amphotericin B (L-AmB) and voriconazole treatment, and antifungal therapy was discontinued after 134 days. Eye examination for the retinopathy didn't show any abnormalities. The patient was discharged with full recovery on day 155.

In conclusion, IA is a rare and life-threatening infection in the neonatal period. To the best of our knowledge, this is the first case of hepatic and mesh infection caused by Aspergillus flavus that was successfully treated with voriconazole and l-AmB.

El texto completo de este artículo está disponible en PDF.

Keywords : Aspergillus flavus, Neonate, Giant omphalocele, Voriconazole, Liposomal amphotericin b


Esquema


© 2022  SFMM. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 32 - N° 2

Artículo 101245- mai 2022 Regresar al número
Artículo precedente Artículo precedente
  • Disseminated histoplasmosis diagnosed by cross-reactivity with the Aspergillus galactomannan antigen in an HIV-positive patient
  • Nathalie Ghorra, Adonis Goushchi, Deborah Konopnicki, Agnès Libois, Katrien Lagrou, Alexandre De Wind, Isabel Montesinos, Marie Hallin, Véronique Yvette Miendje Deyi
| Artículo siguiente Artículo siguiente
  • Evaluation of IFN-γ secretion after stimulation with C. neoformans and C. gattii antigens in individuals with frequent exposure to the fungus
  • Isabel Feitosa Maciel, Roseli Santos de Freitas-Xavier, Adriana Pardini Vicentini, Carlos Fernando Apoliano, Juliana Ruiz Fernandes, Alana dos Santos Dias, Viviane Favero Mazo Gimenes, Gil Benard, Dewton Moraes Vasconcelos

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.